Feature|Videos|December 10, 2024
Breaking barriers: EnzeneX™ to EnzeneX™ 2.0
Author(s)Enzene
Shilpa Gadgil, PhD (VP, Head of Process and Analytical Development, Head of CDMO Development) discusses Enzene's new technologies and the New Jersey site capabilities.
Shilpa Gadgil, PhD, from Enzene, discusses the company's Fully-Connected Continuous Manufacturing™ (FCCM™) platform and EnzeneX™ 2.0 for commercial biologics supply, as well as which large molecules have been successfully produced using the platforms. She also covers Enzene's new biologics site in New Jersey and the bottlenecks the company has overcome regarding transfer and scale-up.
Related Content
Trending on Pharmaceutical Technology
1
MilliporeSigma's Arana Maps the Gaps Holding Back CGT Manufacturing
2
Thermo Fisher's Kane Says AI Is Reshaping How CDMOs Add Value
3
FDA Approves Pfizer’s Breast Cancer Treatment
4
Writing the Biological Script: Scaling DNA Manufacturing for the Next Generation of Therapeutics
5